Prevail Therapeutics
OverviewSuggest Edit
Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. It establishes a pipeline of programs that includes discovery-phase and preclinical development efforts.
| Type | Public | |
| Founded | 2017 | |
| HQ | New York, NY, US | Map |
| Website | prevailtherapeutics.com |
Recent NewsAll News
- Lilly Completes Acquisition of Prevail Therapeutics
- SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout
- Lilly Announces Agreement to Acquire Prevail Therapeutics
- Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations
Key People/Management at Prevail Therapeutics
Asa Abeliovich
CEO & Founder, Director
Franz Hefti
Chief Development Officer
Yong Dai
Chief Technology Officer
Jeffrey Sevigny
Chief Medical Officer
Brett Kaplan
Chief Financial Officer
Emily Minkow
Chief Business Officer
Prevail Therapeutics Office Locations
Prevail Therapeutics has an office in New York
New York, NY, US (HQ)
430 E 29th St #940
Prevail Therapeutics Financials and Metrics
Prevail Therapeutics Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (22.1m) |
EBIT (Q2, 2020) | (22.2m) |
Market capitalization (26-Jan-2021) | 787.7m |
Closing stock price (26-Jan-2021) | 23.0 |
Cash (30-Jun-2020) | 111.1m |
EV | 687.3m |
Prevail Therapeutics's current market capitalization is $787.7 m.
Annual
Annual
Annual
| USD | FY, 2017 |
|---|---|
Debt/Equity | 1.7 x |
Debt/Assets | 0.3 x |
Financial Leverage | 5.5 x |
Prevail Therapeutics Cybersecurity Score
Prevail Therapeutics Online and Social Media Presence
Prevail Therapeutics's Trends
Prevail Therapeutics News and Updates
January 22, 2021
Lilly Completes Acquisition of Prevail Therapeutics
INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's...
December 16, 2020
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout
WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Prevail Therapeutics Inc. (“Prevail”) (NASDAQ GS: PRVL) regarding possible breaches of fiduciary duties and other violations of law related to Prevail’s agreement to be acquired by Eli…
December 15, 2020
Lilly Announces Agreement to Acquire Prevail Therapeutics
INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable...
December 11, 2020
Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 1/2 PROCL…
November 30, 2020
Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the European Commission has granted orphan designation …
November 19, 2020
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) o…
Prevail Therapeutics Blogs
November 02, 2020
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO
Content Import
Mon, 11/02/2020 - 07:02
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO
November 2, 2020 at 7:00 AM …
September 18, 2020
Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Liz.McPherson@…
Fri, 09/18/2020 - 15:05
Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 18, 2020 at 3:04 PM EDT
…
September 10, 2020
Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of Directors
NEW YORK , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of William H.
August 05, 2020
Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
Content Import
Wed, 08/05/2020 - 16:03
Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
August 5, 2020 at 4:01 PM EDT
This release …
July 22, 2020
Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference
Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference
Content Import
Wed, 07/22/2020 - 17:01
Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative…
June 04, 2020
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel
Content Import
Thu, 06/04/2020 - 07:01
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel
June 4, 2020 at 7:00 AM EDT
This release is a backfill from a News Wire
…
Prevail Therapeutics Frequently Asked Questions
When was Prevail Therapeutics founded?
Prevail Therapeutics was founded in 2017.
Who are Prevail Therapeutics key executives?
Prevail Therapeutics's key executives are Asa Abeliovich, Franz Hefti and Yong Dai.
How many employees does Prevail Therapeutics have?
Prevail Therapeutics has 48 employees.
Who are Prevail Therapeutics competitors?
Competitors of Prevail Therapeutics include Molecular Partners, Brii Biosciences and Nordic Nanovector.
Where is Prevail Therapeutics headquarters?
Prevail Therapeutics headquarters is located at 430 E 29th St #940, New York.
Where are Prevail Therapeutics offices?
Prevail Therapeutics has an office in New York.
How many offices does Prevail Therapeutics have?
Prevail Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies